RICERCA E INNOVAZIONE QUALITA E SVILUPPO Presentazione di Umberto Bertazzoni Siena, 12 dicembre 2005.

Slides:

Advertisements

Similar presentations

NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI) NEWMEDS Novel MEthods.

Advertisements

Mental health strategy of the Medical Research Council (UK) Opportunities for European engagement and a role of FEAM European Parliament 22 nd March 2011.

1 Science Technology and Innovation in the chemicals sector: the role of SusChem Andrea Tilche European Commission DG Research Head of the Unit « Environmental.

Support for the coordination of activities TECHNOLOGY PLATFORMS Context, Rationale and State of Play Presentation by Julie Sors European Commission Rotterdam,

Using public procurement to foster research and innovation More Research and Innovation COM(2005) 488 of 12 October 2005 Commission communication to the.

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

Slide title In CAPITALS 50 pt Slide subtitle 32 pt European R&D.

Date: in 12 pts Participation through Marie Sklodovska-Curie Actions: how to raise SME potential through EU researcher mobility Education and Culture Carmela.

Keji Adunmo APRE – Agency for the Promotion of European Research Brussels, 29 Sept Funded by the European Commission's Directorate-General for Research.

Illustrated Story on funding research Europides has got the instruments!

Launch Conference for FP5 Launch Conference for FP5 Essen February 1999 The international role of Community research The international role of Community.

1 1 Living Labs in Piedmont Region Dr. Erica GAY Director Directorate Innovation, Research and University OPEN DAYS, 5 October 2010.

Intellectual Property Rights, Investment and Transfer of Technology in the Pharmaceutical Sector Patrizia Carlevaro Head of the International Aid Unit.

Unlocking the Hidden Potential of Traditional Knowledge: Building Up a Phytopharmaka Market Muscat, February 13 and 14, 2005 Intellectual Property and.

Consortium québécois sur la découverte du médicament Facilitating creative partnerships in biopharmaceutical research Ottawa, November 30 th, 2009 Diane.

EuropeAid Co-operation Office Institutional Capacity Development Operations for the ACP Countries Unit AIDCO C4 Centralised Operations for the ACP Countries.

A European Technology Platform for Sustainable Chemistry Coordinating the research strategies and projects of the European Chemical Industry Marian Mours.

Diabetes and the Health Innovation Network Charles Gostling 19 September, 2013.

HORIZON 2020 STEPHEN FOX FOR KEELE UNIVERSITY 26 TH FEBRUARY 2014.

Oficina AproTECH de AETIC: Información y asesoramiento en la preparación de propuestas de I+D+I The structure of the FP7: Funding schemes,

Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.

Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) The IMI Call and Evaluation Process Eva Lindgren.

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

The evolving role of real-world evidence to support policy and practice CADTH 2015.

Update on a recently launched European R&D endeavour: The Innovative Medicines Initiative (IMI) FERS meeting Brussels, 7 th April 2008.

Stakeholder meeting on the SHIFT²RAIL Strategic Master Plan Manuel Pereira, IST Lisbon ERRAC Vice Chairman 20 th June 2014, Brussels 1.

Enhancing internationalization and innovation capacity through effective cooperation partnerships. Antonis FYSEKIDIS Innovation and Smart Specialisation.

21 October 2005 CNRS Building the Europe of Knowledge Octavi Quintana Trias, Director, European Commission Health Research Directorate, DG Research, Health.

Innovative Medicines Initiative - IMI

Drug Discovery Exchange Fellowship Workshop 9 th -10 th December Mike Hardman IMI EMTRAIN Coordinator.

Governing internal access to data and materials in large research consortia: A mechanism for facilitating translation? Dr Michael Morrison University of.

EU - JAPAN FTA Perspectives from the pharmaceutical industry EESC – Hearing on EU - Japan FTA Brussels, 15 January

AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.

Closing: discussion Tendencies of ESP and Language Learning Technologies Possibilities for Mutual Projects Cooperation Nadežda Stojković, Valentina Nejković,

Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.

The future prospects for clinical trials in Europe Richard Torbett Chief Economist, EFPIA.

Strategic partnerships and alliances Joanne Vincenten European Child Safety Alliance Collaborative work between WHO and the European Child Safety Alliance.

Public Private collaborations to optimise translational research and pathways to patients: IMI Magda Chlebus, Director Science Policy Warsaw, 22 May 2015.

1 Case Study Innovative Medicines Initiative (IMI) Karen Strandgaard EFPIA EuroConference, Brussels April 26th, 2006.

The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.

Plants for the Future Technology Platform for plant biotechnology Prof. Marc Zabeau Vice Chairman, Technology Platform Steering Council Second Seminar.

September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.

Making Good Use of Research Evaluations Anneli Pauli, Vice President (Research)

The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.

Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.

The European Innovation Partnership for asthma: an opportunity for change Samantha Walker PhD, Asthma UK Project Coordinator, EARIP (European Asthma Research.

Policy Research and Innovation Research and Innovation Enhancing and focusing EU international cooperation in research and innovation: A strategic approach.

Slide 1 ANSI Annual Conference 2002 Breaking Down Border: Business, Standards and Trade Standards Outreach and the U.S. Government Faraaz H. Siddiqi Senior.

The Seventh Framework Programme for Research and Technological Development (FP7) supporting innovation Epp Tohver-Bulavs 07. November 2007, Tallinn.

Education about Standardization Doede Bakker CENELEC Vice President Policy Leader of CEN-CENELEC Joint Working Group on EaS/Task Force Masterplan-Operations.

ARETA INTERNATIONAL S.r.l. The Reliable Partner for the Development of Biodrugs in the field of Advanced Therapies.

Technology Platform “Plants for the Future” Member State Consultations on the Stakeholders Proposal for a Strategic Research Agenda

EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.

GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.

Mapping of the European research community – public & private sectors Defining research priorities (Research Agenda) Implementation of research.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

© UEG Presentation by Towards more coordination in health research: a report on the UEG research symposium 16/11/2012 Michael Manns General Assembly.

Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.

The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.

ICPerMed – an International Consortium

Strengthening Australia’s Education Engagement with Latin America

Forum for Collaborative Research:

EXPLORING GLOBAL COOPERATION OPPORTUNITIES

Maximizing the value and the impact of health research in Europe

Innovative Medicines Initiative:

Type and impact of HTA-related scientific advice given during development The variability in HTA organisations and methodologies that are utilised in HTA.

Seeking an IMI funding call in asthma

An Agency Perspective on Plain Language Summaries of Publications

An Agency Perspective on Plain Language Summaries of Publications

Presentation transcript:

RICERCA E INNOVAZIONE QUALITA E SVILUPPO Presentazione di Umberto Bertazzoni Siena, 12 dicembre 2005

Partner italiani valutati e selezionati (totali); Appartenenza Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

Partner italiani valutati e selezionati : 1.2 Biotechnology Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

Partner italiani valutati e selezionati (totali); Appartenenza Priority 1, Life Sciences; Secondo Bando Partner valutati Partner selezionati in lista di priorità

Partner italiani valutati e selezionati : 2.1 Major Diseases Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

Partner italiani valutati e selezionati : 2.3 Poverty Diseases Partner valutati Partner selezionati in lista di priorità Priority 1, Life Sciences; Primo Bando

Quadro generale in negoziazione dei partecipanti e finanziamenti per tipo di partecipante e per paese nel primo bando della priorità 1

Pub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELE IPNoESTREP Partner valutati Partner selezionati in lista di priorità Partner italiani valutati e selezionati : 1.2 Biotechnology Priority 1, Life Sciences; Secondo Bando

Pub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELEPub- Res- Cnt Pri- Res- Cnt Pub- Uni SMELE IPNoESTREP Partner valutati Partner selezionati in lista di priorità Partner italiani valutati e selezionati : 2.1 Major Diseases Priority 1, Life Sciences; Secondo Bando

Appartenenza partecipanti italiani ai progetti in negoziazione terzo bando

in 223 projects (out of 417) 527 participants (some participants appear in more than one project) = 9.4 % of all participants (5611 in total) 43 different private companies (some appear in more than one project) Italian participation in financed projects (calls 1, 2 and 3 ; priority 1 ; fp6)

Innovative Medicines Long term objective: To increase the competitiveness of the European Pharmaceutical industry, and to foster Europe as the most attractive place for pharmaceutical R&D. Thereby enhancing access of innovative medicines to the benefit of patients and society. Aim: To remove major bottlenecks in the drug development process, as identified by industry, and where research is the key. Joint Technology Initiative

Innovative Medicines Initiative Industry (under the leadership of EFPIA) has identified the bottlenecks in agreement with key stakeholders: academia, regulatory agencies, patient organisations, clinical researchers, ethical experts, etc. A Strategic Research Agenda prioritising the research needs and how they should be implemented has been developed by panels of experts.

Innovative Medicines Initiative The Strategic Research Agenda will address bottlenecks in four main areas: Improved prediction – early indications of safety. Improved clinical performance – early indications of efficacy by use of biomarkers. Better knowledge management through collaboration – breaking information barriers at the interfaces. Bridging educational gaps – pre-clinical and clinical research and breaking barriers between disciplines.